Genomics and Bioinformatics Group web site development and maintenance

Division Of Basic Sciences - Nci

Investigators

Linked publications & trials

Abstract

We are successfully maintaining and expanding the Discover web-based tools, with emphasis on CellMiner and the CellMinerCDB's. Our CellMiner "NCI-60 Analysis Tools" section remains a significant resource for pharmacogenomic integration, research, and discovery. It is currently the host for four tools, i) "Cell line signature", ii) Cross-correlation", iii) Pattern comparison", and iv) "Drug vs gene variant/isoforms variant", all of which are designed to reduce the time required by the scientist to integrate molecular and pharmacological data. We continue to upgrade both the software and databases in this section. We currently provide the most inclusive set of molecular and largest compound activity data among any of the large-scale cellular databases. The CellMiner data and tools are creating major opportunities for progress in rational drug discovery, application, and individualization of therapy for cancer patients. As molecular alterations of many types can contribute to the outcome of therapy, the Genomic and Pharmacolgy Facility (GPF) manages and integrates molecular and pharmacological data in such a way that enhances understanding, and facilitates the generation of testable hypotheses. The GPF thus both provides access to high throughput data, and provides software resources that facilitate the mining, understanding, and exploitation of that data. As the DTP drug database contains both unexplored compounds and drugs, it remains an unmatched resource both for recognition of potential novel drugs, and improving understanding of pre-existing ones. The NCI-60 is by far the most comprehensively profiled panel of mammalian cells anywhere. CellMiner CDB expands this approach to include addition databases allowing the user to mine and integrate at will. Currently our Discover and CellMiner sites have 8,400 individual users from 90 countries per month. It has in the past and currently continues to lead to translational discoveries.